Trial Profile
A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06700841 In Healthy Subjects And Subjects With Plaque Psoriasis And Bioavailability Of A Tablet Formulation Relative To Suspension Formulation And The Effect Of Food On A Tablet Formulation Of Pf-06700841
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Brepocitinib (Primary) ; Brepocitinib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 01 Dec 2022 Results (from 5 clinical trials; NCT02310750 NCT03236493 NCT03656952 NCT02969018 NCT02974868 ) assessing Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients published in the Clinical Pharmacology in Drug Development
- 01 Aug 2020 The protocol was amended to include additional renal parameters (e.g., serum cystatin C and cystatin C based estimated glomerular filtration rate measurements). Following the protocol amendment to include the cystatin C based estimated glomerular filtration rate calculation, no additional patients met protocol-based discontinuation criteria based on measures of renal function.
- 12 Dec 2017 Results published in the Journal of Clinical Pharmacology